Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
about
Loss of MutL Disrupts Chk2-dependent Cell Cycle Control Through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: Long-term Follow-up From ACOSOG Z1071 (Alliance).Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer.Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery.Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.Awareness and current knowledge of breast cancer.Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.Pre-operative Endocrine Therapy.Protein biomarkers for subtyping breast cancer and implications for future research.Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer.NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.Lessons in precision oncology from neoadjuvant endocrine therapy trials in ER+ breast cancer.Imaging Tumor Proliferation in Breast Cancer: Current Update on Predictive Imaging BiomarkersNeoadjuvant Model as a Platform for Research in Breast Cancer and Novel Targets under Development in this FieldA New Challenge for Radiologists: Radiomics in Breast CancerImpact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer
P2860
Q38628334-EC7F1884-08AC-41C1-BE53-54ECD33FE57FQ38704901-5D0C204B-9E23-480B-930E-2DECFD9E9B1FQ38726645-2483E039-7FCB-44F6-BEBA-36A18A3E58B0Q39299810-648EA26D-12F4-44BD-B7A7-B264338E74ACQ40179607-0AC64148-FCD1-4B7C-A443-BB7A841432FFQ42176053-7515D01C-1C45-4B1F-ADC5-48185D7ED2BAQ45348344-6A5FE1E4-110E-45F5-9585-1BEE1D4F5DA8Q46143861-BE9307CE-8138-4B69-A77A-517231D84612Q47261659-97C9A41B-F4D0-4073-9A0B-E7B45DC5B0FBQ49558301-4A4BB9E9-0991-4631-AA8E-B614AD67390FQ50093673-45B2C5B7-0307-421D-8F9F-1F04548B34FDQ53183982-5D468184-0ACB-44CA-BCC5-53F5D6601958Q57110625-D8FD61F6-9703-41BB-B5AE-692BFA850607Q57495764-645F82F3-57EB-45E6-906B-7FD627C6EF37Q58579934-4F9096FA-500A-4256-B1E8-29D56E043179Q58799791-F33E480E-87CF-4AE4-B11C-F52516083EC0
P2860
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Ki67 Proliferation Index as a ...... Group Z1031 Trial (Alliance).
@en
Ki67 Proliferation Index as a ...... ons Oncology Group Z1031 Trial
@nl
type
label
Ki67 Proliferation Index as a ...... Group Z1031 Trial (Alliance).
@en
Ki67 Proliferation Index as a ...... ons Oncology Group Z1031 Trial
@nl
prefLabel
Ki67 Proliferation Index as a ...... Group Z1031 Trial (Alliance).
@en
Ki67 Proliferation Index as a ...... ons Oncology Group Z1031 Trial
@nl
P2093
P2860
P356
P1476
Ki67 Proliferation Index as a ...... Group Z1031 Trial (Alliance).
@en
P2093
Chad J Creighton
Cynthia X Ma
D Craig Allred
Eric Winer
Erika Crouch
G Thomas Budd
Gary Unzeitig
Gildy Babiera
P2860
P304
P356
10.1200/JCO.2016.69.4406
P407
P50
P577
2017-01-03T00:00:00Z